Hello Stan,
Here is something to add to that NR.
Fagan Report, Box 450, Grayland, WA 98547
(360) 371-3034
$99 a year.
Reprint: August 4, 1998
At one time, the exclusive territory of this advisory was mining stocks. With gold malingering below $300, its editor, Mr. Brian Fagan, has expanded his territory to other "speculations".
Two of his current speculations are Canadian biotechnology stocks. Mr. Fagan illustrates his recommendation with a chart comparing the seven stages of mineral exploration to seven stages of drug development - from early exploration (pre-clinical screening) to eventual production (eventual sale of new drug). He also suggests a further analogy: speculation in biotech companies like speculation in mining companies can be a form of Russian roulette. Mr. Fagan's two recommended biotechnology picks, both buys, are IGT Pharma Inc. (IGT-VSE,
$1.05) and Inflazyme Pharmaceuticals (IZP-VSE, $0.86). One of IGT's key products is its anti-cancer drug, Anhydrovinblastine, or AVLB, for which it has had "impressive results in reducing cancer tumors" in preclinical trials. The company is now awaiting regulatory go-ahead
to proceed with Phase 1 trials, preliminary testing in humans. Mr. Fagan says, "Studies have shown that companies with a product in Phase 1 clinical trials tend to support a market capitalization of about $25 million. Today IGT has a market capitalization of about $10 million; we're looking at a potential 150-per-cent gain for IGT over a nine-month period." |
